Effect of Induction Cytarabine Dose Intensity on Long-Term Survival in Acute Myelogenous Leukemia: Results of a Randomized, Controlled Study

References

• Buechner T., Hiddemann W. Treatment strategies in acute myeloid leukemia (AML). First-line chemotherapy. Blut 1990; 60: 61–67
   PubMedGoogle Scholar
• Ellison R. R., Holland J. F., Weil M., Jacquillat C., Boi-Ron M., Bernard J., Sawitsky A., Rosner F., Gussoff B., Silver R. T., Karanas A., Cuttner J., Spurr C. L., Hayes D. M., Blom J., Leone L. A., Haurani F., Kyle R., Hutchinson J. L., Forcier R. J., Moon J. H. Arabinosyl cytosine. A useful agent in the treatment of acute leukemia in adults. Blood 1968; 32: 507–523
   PubMed Web of Science ®Google Scholar
• Plunkett W., Liliemark J., Adams T., Nowak B., Estey B., Kantarjian H., Keating M. Evidence that accumulation of ara-C triphosphate in leukemic cells is saturated during high-dose ara-C therapy. (Abstract). Blood 1986; 68: 228a
   Google Scholar
• Phillips G. L., Reece D. E., Shepherd J. D., Barnett M. J., Brown R. A., Frei-Lahr D. A., Klingemann H.-G., Bolwell B. J., Spinelli J. J., Herzig R. H., Herzig G. P. High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelagenous leukemia in adults. Blood 1991; 77: 1429–1435
   PubMed Web of Science ®Google Scholar
• Forman S. J., Nademanee A. P., O'Donnell M. R., Fahey J. L., Snyder D. S., Farhstein M. J., Lazar G. S., Dubois N. J., Blume K. G. High-dose cytosine arabi-noside and daunomycin as primary therapy for adults with acute nonlymphohlastic leukemia: a pilot study. Sem. Oncol. 1985; 12: 114–116
   PubMed Web of Science ®Google Scholar
• Schiller G., Gajewski J., Nimer S., Territo M., Ho W., Lee M., Champlin R. A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukaemia. Brit. J. Hae-matol. 1992; 81: 170–177
   PubMed Web of Science ®Google Scholar
• Bennett J. M., Cdtovsky D. M., Daniel M. T. Proposals for the classification of acute leukaemias. Brit. J. Haematol. 1977; 33: 451–485
   Web of Science ®Google Scholar
• Gajewski J. L., Ho W. G., Nimer S. D., Hirji K. F., Gakelman L., Jacobs A. D., Champlin R. E. Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemia syndrome. J. Clin. Oncol. 1989; 7: 1637–1645
   PubMed Web of Science ®Google Scholar
• Schiller G. J., Nimer S. D., Territo M. C., Ho W. G., Champlin R. E., Gajewski J. L. Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission. J. Clin. Oncol. 1992; 10: 41–46
   PubMed Web of Science ®Google Scholar
• Schiller G. J., Gajewski J., Territo M., Nimer S., Lee M., Belin T., Champlin R. Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. Blood 1992; 80: 2977–2982
   PubMed Web of Science ®Google Scholar
• Winston D. J., Ho W. G., Bruckner D. A., Gale R. P., Champlin R. E. Controlled trials of double beta lactam therapy with cefoperazone plus piperacillin in febrile granulocytopenic patients. Am. J. Med. 1988; 85: 21–30
   PubMed Web of Science ®Google Scholar
• Dixon W. J. W. J. Dixon. University of California Press, Berkeley 1983
   Google Scholar
• Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Statist. Assoc. 1958; 53: 457–481
   Web of Science ®Google Scholar
• Arlin Z. A., Feldman E. J., Finger L., et al. “Quality” remissions: A new target of induction therapy in acute leukemia and the next step in developing curative treatment. Sem. Hematol. 1991; 4(Suppl. 28)44–47
   Google Scholar
• Curtis J. E., Messner H. A., Minden M. D., et al. Megadose cytosine arabinoside (ara-C) for remission induction of acute myelogenous leukemia (AML). Clinical results and laboratory correlation. (Abstract). Blood 1985; 66: 197a
   Google Scholar
• Preisler H., Davis R. B., Kirshner J., Dupre E., Richards R., Hoagland H. C., Kopel S., Levy R. N., Carey R., Schulman P., Gottlieb A. J., McIntyre O. R. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlym-phocytic leukemia: a cancer and leukemia group B study. Blood 1987; 69: 1441–1449
   PubMed Web of Science ®Google Scholar
• Rai K. R., Holland J. F., Gildewell O. J., Weinberg V., Brunner K., Obrecht J. P., Preisler H. D., Nawabi I. W., Prager D., Carey R. W., Cooper M. R., Haurani F., Hutchinson J. L., Silver R. T., Falkson G., Wiernik P., Hoagland H. C., Bloomfield C. D., James G. W., Gottlieb A., Ramanan S. V., Biom J., Nissen N. I., Bank A., Ellison R. R., Kung F., Henry P., McLntyre O. R., Kaan S. K. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood 1981; 58: 1203–1212
   PubMed Web of Science ®Google Scholar
• Tafuri A., Andreeff M. Kinetic rationale for cy-tokine-induced recruitment of myeblostic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 1990; 4: 826–834
   PubMed Web of Science ®Google Scholar
• Gandhi V., Kemena A., Keating M. J., Plunkett W. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lympho-cytic leukemia. Cancer Res. 1992; 52: 897–903
   PubMed Web of Science ®Google Scholar
• Schiller G., Gajewski J., Territo M., Lee M., Nimer S. High-dose Cytarabine and recombundant human granulocyte colony-stimulating factor for the treatment of resistant acute myelogenous leukemia. 24th Congress of the International Society of Haematology. 1992; 221, (Abstract)
   Google Scholar
• Berman E., Heller G., Santorsa J. A., McKenzie S., Gee T., Kempin S., Gulati S., Andreeff M., Kolitz J., Gabri-Live J., Reich L., Mayer K., Keefe D., Trainor K., Schul-Ger A., Penenberg D., Raymond V., O'Reilly R., Jhanwar S., Young C., Clarkson B. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991; 77: 1666–1674
   PubMed Web of Science ®Google Scholar
• Vogler W. R., Velez-Garcia E., Weiner R. S., Flaum M. A., Bartolucci A. A., Omusra G. A., Gerber M. C., Banks P. L. C. A phase III trial comparing idarubicin and daunombicin in combination with cytarabine in acute myelogenous leukemia: A southeastern Cancer Study Group Study. J. Clin. Oncol. 1992; 10: 1103–1111
   PubMed Web of Science ®Google Scholar
• Wiernik P. H., Banks P. L. C., Case D. C., Jr., Arlin Z. A., Periman P. O., Todd M. B., Ritch P. S., Enck R. E., Weitberg A. B. Cytarabine plus idarubicin or du-anorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992; 79: 313–319
   PubMed Web of Science ®Google Scholar
• Foon K. A., Gale R. P. Therapy of acute myelogenous leukemia. Blood Rev. 1992; 6: 15–25
   PubMed Web of Science ®Google Scholar